Elicio Therapeutics Stockholders Approve Directors and Auditor
Elicio Therapeutics (ELTX) held its annual meeting on November 12, 2026, with 66.74% of shares represented. Stockholders approved three directors and ratified Baker Tilly US as auditor. Analysts have mixed views, with a Buy rating and $21 target, while Spark's AI rates it Neutral due to financial performance and technical indicators.

